Differential effects of etifoxine on anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: Any relation to overexpression of central GABAA receptor beta2 subunits?

European Neuropsychopharmacology

Volumn 21, Issue 6, 2011, Pages 457-470

  Verleye, Marc ^a   Dumas, Sylvie ^b   Heulard, Isabelle ^a   Krafft, Nicolas ^a   Gillardin, Jean Marie ^a  

^a Service de Pharmacologie   (France)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

Anticonvulsant; Anxiety related behaviour; Etifoxine; GABAA receptor Beta2 3 subunits; Mouse strains; Papez circuit

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ETIFOXINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; CONVULSION; DRUG BLOOD LEVEL; DRUG RESPONSE; HIPPOCAMPUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; STRESS; THALAMUS NUCLEUS; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; BRAIN; HIPPOCAMPUS; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOTOR ACTIVITY; OXAZINES; RECEPTORS, GABA-A; SEIZURES;

EID: 79955671902     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.09.008     Document Type: Article

References (82)

1. Anisman H., Hayley S., Kelly O., Borowski T., Merali Z. Psychogenic, neurogenic, and systemic stressor effects on plasma corticosterone and behavior: mouse strain-dependent outcomes. Behav. Neurosci. 2001, 115:443-454.
2. Augustsson H., van de Weerd H.A., Kruitwagen C.L., Baumans V. Effect of enrichment on variation and results in the light/dark test. Lab Anim. 2003, 37:328-340.
3. Belelli D., Lambert J.L., Peters J.A., Wafford K., Whiting P.J. The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. Proc. Natl Acad. Sci. 1997, 94:11031-11036.
4. Belzung C. The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. Behav. Pharmacol. 2001, 12:451-460.
5. Bhatnagar S., Huber R., Lazar E., Pych L., Vining C. Chronic stress alters behavior in the conditioned defensive burying test: role of the posterior paraventricular thalamus. Pharmacol. Biochem. Behav. 2003, 76:343-349.
6. Blednov Y.A., Jung S., Alva H., Wallace D., Rosahl T., Whiting P.J., Harris R.A. Deletion of the alpha1 or beta2 subunit of GABAA receptors reduces actions of alcohol and other drugs. J. Pharmacol. Exp. Ther. 2003, 304:30-36.
7. Caldji C., Diorio J., Anisman H., Meaney M.J. Maternal behavior regulates benzodiazepine/GABAA receptor subunit expression in brain regions associated with fear in BALB/c and C57BL/6 mice. Neuropsychopharmacology 2004, 29:1344-1352.
8. Cameron O.G., Huang G.C., Nichols T., Koeppe R.A., Minoshima S., Rose D., Frey K.A. Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. Arch. Gen. Psychiatry 2007, 64:793-800.
9. Campeau S., Davis M. Involvement of subcortical and cortical afferents to the lateral nucleus of the amygdala in fear conditioning measured with fear-potentiated startle in rats trained concurrently with auditory and visual conditioned stimuli. J. Neurosci. 1995, 15:2312-2327.
10. Chaouloff F., Durand M., Mormède P. Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Behav. Brain Res. 1997, 85:27-35.
11. Chapouthier G., Bondoux D., Martin B., Desforges C., Launay J.M. Genetic difference in sensitivity to beta-carboline: evidence for the involvement of brain benzodiazepine receptors. Brain Res. 1991, 553:342-346.
12. Clément Y., Calatayud F., Belzung C. Genetic basis of anxiety-like behaviour: a critical review. Brain Res. Bull. 2001, 57:57-71.
13. Cloos J.M., Ferreira V. Current use of benzodiazepines in anxiety disorders. Curr. Opin. Psychiatry 2009, 22:90-95.
14. Crawley J., Davis L.G. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Res. Bull. 1982, 8:609-612.
15. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 1980, 13:167-170.
16. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. 2005, 4:775-790.
17. Depino A.M., Gross C. Simultaneous assessment of autonomic function and anxiety-related behavior in BALB/c and C57BL/6 mice. Behav. Brain Res. 2007, 177:254-260.
18. Ducottet C., Belzung C. Behaviour in the elevated plus-maze predicts coping after subchronic mild stress in mice. Physiol. Behav. 2004, 81:417-426.
19. Eggers A.E. Redrawing Papez' circuit: a theory about how acute stress becomes chronic and causes disease. Med. Hypotheses 2007, 69:852-857.
20. Fernandez C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav. 1996, 54:31-40.
21. Fernandez S.P., Mewett K.N., Hanrahan J.R., Chebib M., Johnston G.A. Flavan-3-ol derivatives are positive modulators of GABA(A) receptors with higher efficacy for the alpha(2) subtype and anxiolytic action in mice. Neuropharmacology 2008, 55:900-907.
22. Gale K. Progression and generalization of seizure discharge: anatomical and neurochemical substrates. Epilepsia 1988, 29(Suppl 2):S15-S34.
23. Gee K.W., Tran M.B., Hogenkamp D.J., Johnstone T.B., Bagnera R.E., Yoshimura R.F., Huang J.C., Belluzzi J.D., Whittemore E.R. Limiting activity at beta1-subunit containing GABAA receptor subtypes reduces ataxia. J. Pharmacol. Exp. Ther. 2010, 332:1040-1053.
24. Gorman J.M., Kent J.M., Sullivan G.M., Coplan J.D. Neuroanatomical hypothesis of panic disorder, revised. Am. J. Psychiatry 2000, 157:493-505.
25. Griebel G., Belzung C., Misslin R., Vogel E. The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav. Pharmacol. 1993, 4:637-644.
26. Griebel G., Belzung C., Perrault G., Sanger D.J. Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 2000, 148:164-170.
27. Groves J.O., Guscott M.R., Hallett D.J., Rosahl T.W., Pike A., Davies A., Wafford K.A., Reynolds D.S. The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole. Eur. J. Neurosci. 2006, 24:167-174.
28. Hackler E.A., Airey D.C., Shannon C.C., Sodhi M.S., Sanders-Bush E. 5-HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice. Neurosci. Res. 2006, 55:96-104.
29. Hamon A., Morel A., Hue B., Verleye M., Gillardin J.M. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology 2003, 45:293-303.
30. Hasler G., Nugent A.C., Carlson P.J., Carson R.E., Geraci M., Drevets W.C. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch. Gen. Psychiatry 2008, 65:1166-1175.
31. Herve D., Tassin J.P., Barthelemy C., Blanc G., Lavielle S., Glowinski J. Difference in the reactivity of the mesocortical dopaminergic neurons to stress in the BALB/C and C57 BL/6 mice. Life Sci. 1979, 25:1659-1664.
32. Hode Y., Ratomponirina C., Gobaille S., Maitre M., Kopp C., Misslin R. Hypoexpression of benzodiazepine receptors in the amygdala of neophobic BALB/c mice compared to C57BL/6 mice. Pharmacol. Biochem. Behav. 2000, 65:35-38.
33. Im W.B., Pregenzer J.F., Thomsen D.R. Effects of GABA and various allosteric ligands on TBPS binding to cloned rat GABA(A) receptor subtypes. Br. J. Pharmacol. 1994, 112:1025-1030.
34. Iwata J., LeDoux J.E., Meeley M.P., Arneric S., Reis D.J. Intrinsic neurons in the amygdaloid field projected to by the medial geniculate body mediate emotional responses conditioned to acoustic stimuli. Brain Res. 1986, 383:195-214.
35. Johnston G.A. GABA(A) receptor channel pharmacology. Curr. Pharm. Des. 2005, 11:1867-1885.
36. Kash S.F., Tecott L.H., Hodge C., Baekkeskov S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 1999, 96:1698-1703.
37. Korpi E.R., Sinkkonen S.T. GABA(A) receptor subtypes as targets for neuropsychiatric drug development. Pharmacol. Ther. 2006, 109:12-32.
38. Korpi E.R., Grunder G., Luddens H. Drug interactions at GABA(A) receptors. Prog. Neurobiol. 2002, 67:113-159.
39. Kruse H.J., Kuch H. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. Arzneimittelforschung 1985, 35:133-135.
40. Lalonde R., Strazielle C. Relations between open-field, elevated plus-maze, and emergence tests in C57BL/6J and BALB/c mice injected with GABA-and 5HT-anxiolytic agents. Fundam. Clin. Pharmacol. 2010, 24:365-376.
41. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
42. Lepicard E.M., Joubert C., Hagneau I., Perez-Diaz F., Chapouthier G. Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice. Pharmacol. Biochem. Behav. 2000, 67:739-748.
43. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92:180-185.
44. McKernan R.M., Whiting P.J. Which GABAA-receptor subtypes really occur in the brain?. Trends Neurosci. 1996, 19:139-143.
45. Mihic S.J., Van Berckel B.N., O'Dowd B.F., Nguyen T., Wu P.H. Effects of sedatives on GABA-mediated chloride flux into cerebral cortical microsacs prepared from emotional and non-emotional mice. Eur. J. Pharmacol. 1992, 218:283-286.
46. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 2003, 70:83-244.
47. Mohler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res. 2006, 326:505-516.
48. Moutsimilli L., Farley S., Dumas S., El Mestikawy S., Giros B., Tzavara E.T. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 2005, 49:890-900.
49. Nagakura Y., Naitoh Y., Kamato T., Yamano M., Miyata K. Compounds possessing 5-HT3 receptor antagonistic activity inhibit intestinal propulsion in mice. Eur. J. Pharmacol. 1996, 311:67-72.
50. Nguyen N., Fakra E., Pradel V., Jouve E., Alquier C., Le Guern M.E., Micallef J., Blin O. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum. Psychopharmacol. 2006, 21:139-149.
51. Paxinos G., Franklin G. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego, USA. 2nd ed.
52. Pirker S., Schwarzer C., Wieselthaler A., Sieghart W., Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000, 101:815-850.
53. Poulter M.O., Du L., Zhurov V., Merali Z., Anisman H. Plasticity of the GABA(A) receptor subunit cassette in response to stressors in reactive versus resilient mice. Neuroscience 2010, 165:1039-1051.
54. Pratt J.A. The neuroanatomical basis of anxiety. Pharmacol. Ther. 1992, 55:149-181.
55. Pregenzer J.F., Im W.B., Carter D.B., Thomsen D.R. Comparison of interactions of [3H]muscimol, t-butylbicyclophosphoro[35S]thionate, and [3H]flunitrazepam with cloned gamma-aminobutyric acidA receptors of the alpha 1 beta 2 and alpha 1 beta 2 gamma 2 subtypes. Mol. Pharmacol. 1993, 43:801-806.
56. Reynolds D.S., Rosahl T.W., Cirone J., O'Meara G.F., Haythornthwaite A., Newman R.J., Myers J., Sur C., Howell O., Rutter A.R., Atack J., Macaulay A.J., Hadingham K.L., Hutson P.H., Belelli D., Lambert J.J., Dawson G.R., McKernan R., Whiting P.J., Wafford K.A. Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. J. Neurosci. 2003, 23:8608-8617.
57. Robertson H.A. Benzodiazepine receptors in "emotional" and "non-emotional" mice; comparison of four strains. Eur. J. Pharmacol. 1979, 56:163-166.
58. Rodgers R.J., Johnson N.J. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 1995, 52:297-303.
59. Rupprecht R., Eser D., Zwanzger P., Moller H.J. GABAA receptors as targets for novel anxiolytic drugs. World J. Biol. Psychiatry 2006, 7:231-237.
60. Schlichter R., Rybalchenko V., Poisbeau P., Verleye M., Gillardin J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 2000, 39:1523-1535.
61. Schmitt U., Luddens H., Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J. Neural Transm. 2002, 109:871-880.
62. Seredenin S.B., Lapitskaya A.S., Nadorov S.A., Kudrin V.S., Badyshtov B.A. Multidimensional assessment of differences in monoamine metabolism in C57BL/6 and BALB/c mice. Bull. Exp. Biol. Med. 2000, 129:487-490.
63. Sieghart W. Structure, pharmacology, and function of GABAA receptor subtypes. Adv. Pharmacol. 2006, 54:231-263.
64. Sigel E., Buhr A. The benzodiazepine binding site of GABAA receptors. Trends Pharmacol. Sci. 1997, 18:425-429.
65. Smith T.A. Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. Br. J. Biomed. Sci. 2001, 58:111-121.
66. Smith A.J., Oxley B., Malpas S., Pillai G.V., Simpson P.B. Compounds exhibiting selective efficacy for different beta subunits of human recombinant gamma-aminobutyric acid A receptors. J. Pharmacol. Exp. Ther. 2004, 311:601-609.
67. Squires R.F., Casida J.E., Richardson M., Saederup E. [35S]t-butylbicyclophosphorothionate binds with high affinity to brain-specific sites coupled to gamma-aminobutyric acid-A and ion recognition sites. Mol. Pharmacol. 1983, 23:326-336.
68. Stork O., Ji F.Y., Kaneko K., Stork S., Yoshinobu Y., Moriya T., Shibata S., Obata K. Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res. 2000, 865:45-58.
69. Sur C., Wafford K.A., Reynolds D.S., Hadingham K.L., Bromidge F., Macaulay A., Collinson N., O'Meara G., Howell O., Newman R., Myers J., Atack J.R., Dawson G.R., McKernan R.M., Whiting P.J., Rosahl T.W. Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice. J. Neurosci. 2001, 21:3409-3418.
70. Tang X., Orchard S.M., Sanford L.D. Home cage activity and behavioral performance in inbred and hybrid mice. Behav. Brain Res. 2002, 136:555-569.
71. Tang X., Yang L., Fishback N.F., Sanford L.D. Differential effects of lorazepam on sleep and activity in C57BL/6J and BALB/cJ strain mice. J. Sleep Res. 2009, 18:365-373.
72. Tannenbaum, B., Anisman, H., 2003. Impact of chronic intermittent challenges in stressor-susceptible and resilient strains of mice. Biol Psychiatry. 2003 May 15;53(10):921-7 53, 292-303.
73. Trullas R., Skolnick P. Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology (Berl) 1993, 111:323-331.
74. Ugale R.R., Sharma A.N., Kokare D.M., Hirani K., Subhedar N.K., Chopde C.T. Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats. Brain Res. 2007, 1184:193-201.
75. Verleye M., Gillardin J.M. Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. Physiol. Behav. 2004, 82:891-897.
76. Verleye M., Schlichter R., Gillardin J.M. Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex. NeuroReport 1999, 10:3207-3210.
77. Verleye M., Heulard I., Nuss P., Gillardin J.M. Effects of stress and etifoxine on pentobarbital-induced loss of righting reflex in Balb/cByJ and C57BL/6J mice. Neurosci. Lett. 2003, 353:127-130.
78. Verleye M., Akwa Y., Liere P., Ladurelle N., Pianos A., Eychenne B., Schumacher M., Gillardin J.M. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol. Biochem. Behav. 2005, 82:712-720.
79. Williams C.L., Villar R.G., Peterson J.M., Burks T.F. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology 1988, 94:611-621.
80. Wisden W., Laurie D.J., Monyer H., Seeburg P.H. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci. 1992, 12:1040-1062.
81. Yilmazer-Hanke D.M., Roskoden T., Zilles K., Schwegler H. Anxiety-related behaviour and densities of glutamate, GABAA, acetylcholine and serotonin receptors in the amygdale of seven inbred mouse strains. Behav. Brain Res. 2003, 145:145-159.
82. Zezula J., Slany A., Sieghart W. Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits. Eur. J. Pharmacol. 1996, 301:207-214.